Moleculin Biotech Inc expected to post a loss of $1.54 a share - Earnings Preview

Moleculin Biotech

08/08/2026 24:07

Moleculin Biotech Inc MBRX.OQ MBRX.O is expected to  show no change in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Moleculin Biotech Inc is for a loss of $1.54 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Moleculin Biotech Inc is $22.00, about 5,272.4% above its last closing price of $0.41
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.66
-1.66
-3.54
Missed
-112.8
Dec. 31 2026
-6.41
-6.11
13.04
Beat
313.3
Sep. 30 2025
-5.00
-4.87
-17.00
Missed
-248.7​
Jun. 30 2025
-9.80
-9.08
-12.25
Missed
-34.9
​​Mar. 31 2025
-13.22
-13.87
-17.25
Missed
-24.3
Dec. 31 2024
-33.25
-32.08
-9.32
Beat
70.9​
Sep. 30 2024
-61.00
-61.00
-71.25
Missed
-16.8
Jun. 30 2024
-60.65
-62.75
-42.50
Beat
32.3
This summary was machine generated August 7 at 23:07 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)